Vesigen Therapeutics

Bayer AG 's freshly-inked CAR-T alliance with Atara Biotherapeutics, Inc. is another key piece in the German company's strategy of establishing itself as a leading player in the emerging fields of g

The US presidential election slowed the flow of venture capital funding announcements during the first week of November, but the flood of new biopharmaceutical VC deals resumed during the second week

Bayer AG has hit the acquisition trail again, having just agreed to buy the UK's KaNDy Therapeutics Ltd. , and a number of other deals are in the pipeline following a revamp of its partnering activi